DICE Therapeutics, Inc. Common Stock
DICE
DICE was delisted on the 8th of August, 2023.
39 hedge funds and large institutions have $794M invested in DICE Therapeutics, Inc. Common Stock in 2021 Q3 according to their latest regulatory filings, with 39 funds opening new positions, increasing their positions, reducing their positions, and closing their positions.
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
RCM
RA Capital Management
Boston,
Massachusetts
|
+$177M |
| 2 |
DCM
Driehaus Capital Management
Chicago,
Illinois
|
+$69.9M |
| 3 |
EAM
Eventide Asset Management
Boston,
Massachusetts
|
+$63.7M |
| 4 |
Janus Henderson Group
London,
|
+$63.5M |
| 5 |
T. Rowe Price Associates
Baltimore,
Maryland
|
+$51.2M |
Top Sellers
DICE Hedge Fund Activity: Q3 2021 in Review
39 of the 5,728 institutional investors tracked by Wall St. Rank reported a position in DICE Therapeutics, Inc. Common Stock (DICE) for Q3 2021, worth a combined $794M.
Buyers outnumbered sellers: 39 funds opened new DICE positions and 0 closed out — a net gain of 39 holders — while 0 added to existing stakes and 0 trimmed.
The largest buyer was RA Capital Management, opening a new position worth an estimated $177M.
- 39 institutional investors held DICE Therapeutics, Inc. Common Stock (DICE) as of Q3 2021, up from 0 in Q2 2021.
- Funds reported $794M of DICE Therapeutics, Inc. Common Stock stock for Q3 2021.
- 39 funds opened new DICE Therapeutics, Inc. Common Stock positions in Q3 2021 and 0 closed out, a net change of +39 holders.
- The largest DICE Therapeutics, Inc. Common Stock buyer in Q3 2021 was RA Capital Management, an estimated $177M added.
Based on aggregated 13F filings for Q3 2021.